Robert Dreicer, MD

Articles

Dr. Dreicer on the Clinical Implications of the JAVELIN Bladder 100 Trial in Urothelial Cancer

July 28th 2021

Robert Dreicer, MD, discusses the clinical implications of the phase 3 JAVELIN Bladder 100 trial in locally advanced or metastatic urothelial cancer.

Dr. Dreicer on the Initial Findings With Sabizabulin in mCRPC

July 13th 2021

Robert Dreicer, MD, discusses the initial findings with sabizabulin in metastatic castration-resistant prostate cancer.

Dr. Dreicer on the Goals of the Phase 3 VERACITY Trial With VERU-111 in mCRPC

June 8th 2021

Robert Dreicer, MD, discusses the goals of the phase 3 VERACITY trial with VERU-111 in patients with metastatic castration-resistant prostate cancer.

Dr. Dreicer on Response to Immunotherapy in Urothelial Cancer

September 6th 2019

Robert Dreicer, MD, deputy director, UVA Cancer Center, director, Solid Tumor Oncology in the Division of Hematology/Oncology, and a professor of Medicine and Urology, University of Virginia Health System, discusses response to immunotherapy in urothelial cancer.

Dr. Dreicer on Biomarkers of Response to Immunotherapy in Urothelial Cancer

April 5th 2019

Robert Dreicer, MD, professor of medicine and urology, University of Virginia Health System, section chief, Medical Oncology, deputy director, UVA Cancer Center, discusses biomarkers of response to immunotherapy in patients with metastatic urothelial cancer.

Dr. Dreicer on Ongoing Trials in Prostate Cancer

July 19th 2017

Robert Dreicer, MD, professor, University of Virginia Health System, discusses ongoing trials investigating emerging treatments for patients with prostate cancer.

Dr. Dreicer on the Current Role of Abiraterone and Enzalutamide in Prostate Cancer

April 11th 2017

Robert Dreicer, MD, professor, University of Virginia Health System, discusses the current role of abiraterone acetate (Zytiga) and enzalutamide (Xtandi) for patients with prostate cancer.

Dr. Dreicer on Abiraterone and Enzalutamide in Prostate Cancer

March 24th 2017

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses abiraterone acetate (Zytiga) and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Dreicer on Future Treatment Approaches in Prostate Cancer

February 17th 2017

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses the progress he would like to see accomplished in the field of metastatic castration-resistant prostate cancer.

Dr. Dreicer Discusses Challenges of Radium-223 in Prostate Cancer

January 18th 2017

Robert Dreicer, MD, associate director for clinical research and deputy director of the University of Virginia Cancer Center, discusses the questions that surround radium-223.

Dr. Dreicer on Ongoing Trials in Prostate Cancer

January 11th 2017

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses novel agents or clinical trials in development designed to help guide treatment decisions for patients with prostate cancer.

Dr. Robert Dreicer on Overcoming Resistance Pathways in mCRPC

November 21st 2016

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses next-generation antiandrogen therapies in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Dreicer on Combination Trials With Radium-223 in mCRPC

November 12th 2016

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses the potential of combination regimens involving radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Dreicer on Resistance to Antiandrogen Therapy in Prostate Cancer

September 8th 2016

Robert Dreicer, MD, Division of Hematology/Oncology, Department of Medicine, University of Virginia Health System, discusses resistance to antiandrogen therapy in prostate cancer.

Dr. Dreicer on the Optimal Use of Radium-223 in Prostate Cancer

March 21st 2016

Robert Dreicer, MD, professor, Department of Medicine, Division of Hematology/Oncology, University of Virginia Health System, discusses the optimal use of radium-223 dichloride (Xofigo) for patients with metastatic castration-resistant prostate cancer.

Dr. Dreicer on Sequencing Therapies for Patients with Prostate Cancer

March 16th 2015

Robert Dreicer, MD, MS, FACP, FASCO, Division of Hematology and Oncology, Department of Medicine, University of Virginia School of Medicine, discusses sequencing therapies in prostate cancer.

Dr. Dreicer on Trial Endpoints in Prostate Cancer

April 29th 2014

Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, comments on current clinical trial endpoints in prostate cancer.

Dr. Dreicer on Next-Generation AR Therapies in CRPC

April 14th 2014

Robert Dreicer, MD, MS, discusses next-generation anti-androgen therapies for patients with castration-resistant prostate cancer.

Dr. Dreicer on Combining Agents With Immunotherapies

March 27th 2014

Robert Dreicer, MD, MS, discusses combining and sequencing agents with immunotherapies for the treatment of prostate cancer.

Dr. Dreicer on Prostate Cancer Drug Development Challenges

April 23rd 2013

Robert Dreicer, MD, MS, from the Cleveland Clinic in Ohio, discusses challenges facing the development of new lyase inhibitors and androgen receptor antagonists as treatments for men with prostate cancer.